4.7 Article

Mortality Outcomes With Intensive Blood Pressure Targets in Chronic Kidney Disease Patients: A Pooled Individual Patient Data Analysis From Randomized Trials

Journal

HYPERTENSION
Volume 73, Issue 6, Pages 1275-1282

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/HYPERTENSIONAHA.119.12697

Keywords

blood pressure; cardiovascular disease; chronic kidney disease; morbidity; mortality

Funding

  1. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Ask authors/readers for more resources

Hypertension is highly prevalent and morbid in the chronic kidney disease population, and blood pressure (BP) targets for this population are unclear. We aimed to compare all-cause mortality outcomes with intensively targeting systolic BP to <130 mmHg versus a standard of <140 mmHg. Individual patient data from 4983 chronic kidney disease patients with hypertension were pooled from 4 multicenter randomized control trialsAASK (African American Study of Kidney Disease and Hypertension), ACCORD (Action to Control Cardiovascular Risk in Diabetes), MDRD (Modification of Diet in Renal Disease), and the SPRINT (Systolic Blood Pressure Intervention Trial). Patients were assigned their trial-assigned randomized intervention groupstandard (n=2474) versus intensive (n=2509) BP targets. Additional analyses included excluding patients with a glomerular filtration rate 60 mL/min per 1.73 m(2) along with those undergoing intensive glycemic control. The primary outcome was all-cause mortality. Average achieved BP was 125.0 mmHg in the intensive group and 136.9 mmHg in the standard group. In the primary analysis, the all-cause mortality rate trended towards improved outcomes with intensive treatment but was not statistically significant (hazard ratio: 0.87 [0.69-1.08]; P=0.21). One hundred seventy-three of 2474 patients (1.95% per year) in the standard group and 153 of 2509 patients (1.71% per year) in the intensive group died. After excluding patients with higher glomerular filtration rate values and those undergoing intensive glycemic control, there was a statistically significant decrease in all-cause mortality rate (hazard ratio: 0.79 [0.63-1.00]; P=0.048). An intensive BP target of <130 mmHg decreases all-cause mortality when compared with a standard target of <140 mmHg in patients with chronic kidney disease stage 3 or greater who are not undergoing intensive glycemic therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available